Market overview
The global multiplex sepsis biomarker panels market is worth USD 203 mn in 2026 and is forecast to reach USD 632 mn by 2036, growing at a 12.0% CAGR. United States is the largest country market and Central laboratory analysers is the largest by platform segment.
| Scope | Blood tests that measure several host-response biomarkers at once to detect sepsis or predict its course, run on lab analysers and point-of-care platforms. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 180 mn |
| Value 2026 | USD 203 mn |
| Value 2036 | USD 632 mn |
| CAGR 2026-2036 | 12.0% |
| Volume 2026 | 5.06 million tests |
| Volume 2036 | 14.9 million tests |
| Average price 2026 | USD 40.2 per test |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Multiplex Sepsis Biomarker Panels market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 203 mn |
| 2027 | USD 228 mn |
| 2028 | USD 255 mn |
| 2029 | USD 286 mn |
| 2030 | USD 320 mn |
| 2031 | USD 358 mn |
| 2032 | USD 401 mn |
| 2033 | USD 450 mn |
| 2034 | USD 504 mn |
| 2035 | USD 564 mn |
| 2036 | USD 632 mn |
Multiplex Sepsis Biomarker Panels market segmentation
By platform
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Central laboratory analysers | 48.0% | 35.8% | USD 98 mn | 8.8% |
| Point-of-care systems | 34.0% | 43.2% | USD 69 mn | 14.7% |
| Molecular host-response | 18.0% | 21.0% | USD 37 mn | 13.7% |
By end use
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Emergency departments | 52.0% | 54.0% | USD 106 mn | 12.4% |
| Intensive care units | 30.0% | 27.3% | USD 61 mn | 10.9% |
| Other hospital wards | 18.0% | 18.7% | USD 37 mn | 12.4% |
By biomarker class
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Inflammatory markers | 38.0% | 34.0% | USD 77 mn | 10.8% |
| Cell-surface and immune markers | 22.0% | 26.0% | USD 45 mn | 13.9% |
| Host-response gene signatures | 20.0% | 25.0% | USD 41 mn | 14.5% |
| Metabolic and coagulation markers | 20.0% | 15.0% | USD 41 mn | 8.8% |
By specimen
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Whole blood | 52.0% | 52.0% | USD 106 mn | 12.0% |
| Plasma and serum | 36.0% | 33.0% | USD 73 mn | 11.0% |
| Other specimens | 12.0% | 15.0% | USD 24 mn | 14.5% |
By test setting
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Central laboratory | 48.0% | 40.0% | USD 98 mn | 10.0% |
| Emergency department point-of-care | 30.0% | 36.0% | USD 61 mn | 14.1% |
| ICU bedside | 22.0% | 24.0% | USD 45 mn | 13.0% |
Top 25 countries for multiplex sepsis biomarker panels by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 90.5% of 2026 revenue and the 25 countries below together hold 97.3%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 81 mn | 40.0% | USD 245 mn | 11.7% |
| 2 | Germany | USD 20 mn | 10.0% | USD 59 mn | 11.2% |
| 3 | China | USD 18 mn | 9.0% | USD 75 mn | 15.2% |
| 4 | Japan | USD 14 mn | 7.0% | USD 37 mn | 10.1% |
| 5 | France | USD 12 mn | 6.0% | USD 35 mn | 11.2% |
| 6 | United Kingdom | USD 10 mn | 5.0% | USD 30 mn | 11.5% |
| 7 | Italy | USD 8.1 mn | 4.0% | USD 23 mn | 11.1% |
| 8 | Spain | USD 7.1 mn | 3.5% | USD 20 mn | 11.0% |
| 9 | India | USD 6.1 mn | 3.0% | USD 25 mn | 15.3% |
| 10 | Brazil | USD 6.1 mn | 3.0% | USD 20 mn | 12.7% |
| 11 | Canada | USD 2.8 mn | 1.4% | USD 8.8 mn | 12.2% |
| 12 | South Korea | USD 2.3 mn | 1.1% | USD 7.3 mn | 12.1% |
| 13 | Netherlands | USD 1.9 mn | 0.9% | USD 6.1 mn | 12.1% |
| 14 | Australia | USD 1.4 mn | 0.7% | USD 4.5 mn | 12.2% |
| 15 | Belgium | USD 1.1 mn | 0.6% | USD 3.5 mn | 12.0% |
| 16 | Sweden | USD 0.96 mn | 0.5% | USD 3.0 mn | 12.2% |
| 17 | Mexico | USD 0.79 mn | 0.4% | USD 2.5 mn | 12.0% |
| 18 | Switzerland | USD 0.63 mn | 0.3% | USD 2.0 mn | 12.4% |
| 19 | Austria | USD 0.47 mn | 0.2% | USD 1.4 mn | 12.0% |
| 20 | Taiwan | USD 0.37 mn | 0.2% | USD 1.1 mn | 12.0% |
| 21 | Israel | USD 0.31 mn | 0.1% | USD 1.0 mn | 12.7% |
| 22 | Poland | USD 0.24 mn | 0.1% | USD 0.76 mn | 12.0% |
| 23 | Turkey | USD 0.20 mn | 0.1% | USD 0.63 mn | 12.0% |
| 24 | Singapore | USD 0.16 mn | 0.08% | USD 0.51 mn | 12.0% |
| 25 | Denmark | USD 0.14 mn | 0.07% | USD 0.44 mn | 12.0% |
| Rest of world | USD 5.4 mn | 2.7% | USD 17 mn | 12.1% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- bioMerieux
- Roche Diagnostics
- Beckman Coulter
- Abbott
- Thermo Fisher Scientific
- Siemens Healthineers
Group 2: Regional and specialist players
- Cytovale
- MeMed
- Immunexpress
- Mindray
- Snibe Diagnostic
- Sysmex
Group 3: Emerging and niche players
- Inflammatix
- Prenosis
- sphingotec
- T2 Biosystems
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the multiplex sepsis biomarker panels market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 12.0% is calculated from the resulting values.
The market is divided by platform, by end use, by biomarker class, by specimen, by test setting. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the multiplex sepsis biomarker panels market?
The global multiplex sepsis biomarker panels market is estimated at USD 180 mn in 2025 and USD 203 mn in 2026.
How fast will the multiplex sepsis biomarker panels market grow?
It is forecast to reach USD 632 mn by 2036, a compound annual growth rate of 12.0% from 2026, an increase of USD 428 mn.
Which country is the largest market for multiplex sepsis biomarker panels?
United States is the largest market by revenue at USD 81 mn in 2026, 40.0% of the global total. The three largest countries together hold 59.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 15.3% a year from 2026 to 2036.
Which multiplex sepsis biomarker panels segment is largest?
In the by platform split, Central laboratory analysers is the largest segment with 48.0% of 2026 revenue.
Who are the leading multiplex sepsis biomarker panels companies?
Global leaders include bioMerieux, Roche Diagnostics, Beckman Coulter, Abbott.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Carboxylate-Modified Magnetic BeadsUSD 201 mn · 8.0% CAGR
- Pharma Peeler CentrifugeUSD 191 mn · 5.8% CAGR
- Vibriosis Treatment ProductsUSD 191 mn · 5.8% CAGR
- Absorbable PGA Surgical SuturesUSD 228 mn · 3.5% CAGR
- Diagnostic Exosome BiomarkersUSD 242 mn · 15.0% CAGR
- Continuous Peripheral Nerve Block CatheterUSD 243 mn · 5.0% CAGR
- Medical Device Cyber Risk QuantificationUSD 244 mn · 15.0% CAGR
- Dengue VaccinesUSD 247 mn · 22.0% CAGR
← Multi-Organ Transplant Monitoring Muscle Stimulation Devices →